374 related articles for article (PubMed ID: 28148699)
1. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review.
Shiozawa A; Szabo SM; Bolzani A; Cheung A; Choi HK
J Rheumatol; 2017 Mar; 44(3):388-396. PubMed ID: 28148699
[TBL] [Abstract][Full Text] [Related]
2. Serum uric acid levels and the risk of flares among gout patients in a US managed care setting.
Shiozawa A; Buysman EK; Korrer S
Curr Med Res Opin; 2017 Jan; 33(1):117-124. PubMed ID: 27659103
[TBL] [Abstract][Full Text] [Related]
3. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Ann Rheum Dis; 2021 Nov; 80(11):1483-1490. PubMed ID: 34158371
[TBL] [Abstract][Full Text] [Related]
4. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
Juraschek SP; Kovell LC; Miller ER; Gelber AC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
[TBL] [Abstract][Full Text] [Related]
5. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
7. Treatment target and followup measures for patients with gout: a systematic literature review.
Andrés M; Sivera F; Falzon L; van der Heijde DM; Carmona L
J Rheumatol Suppl; 2014 Sep; 92():55-62. PubMed ID: 25180129
[TBL] [Abstract][Full Text] [Related]
8. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
Wu EQ; Patel PA; Mody RR; Yu AP; Cahill KE; Tang J; Krishnan E
J Rheumatol; 2009 May; 36(5):1032-40. PubMed ID: 19369467
[TBL] [Abstract][Full Text] [Related]
9. Serum urate levels and gout flares: analysis from managed care data.
Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
[TBL] [Abstract][Full Text] [Related]
10. Serum urate and incidence of kidney disease among veterans with gout.
Krishnan E; Akhras KS; Sharma H; Marynchenko M; Wu E; Tawk RH; Liu J; Shi L
J Rheumatol; 2013 Jul; 40(7):1166-72. PubMed ID: 23678154
[TBL] [Abstract][Full Text] [Related]
11. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Bakris GL; Doghramji PP; Keenan RT; Silber SH
Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
[TBL] [Abstract][Full Text] [Related]
12. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
[TBL] [Abstract][Full Text] [Related]
14. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
[TBL] [Abstract][Full Text] [Related]
15. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
16. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data.
Essex MN; Hopps M; Bienen EJ; Udall M; Mardekian J; Makinson GT
J Clin Rheumatol; 2017 Apr; 23(3):160-166. PubMed ID: 28248798
[TBL] [Abstract][Full Text] [Related]
18. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
[TBL] [Abstract][Full Text] [Related]
19. Gender-specific risk factors for incident gout: a prospective cohort study.
Chen JH; Yeh WT; Chuang SY; Wu YY; Pan WH
Clin Rheumatol; 2012 Feb; 31(2):239-45. PubMed ID: 21761146
[TBL] [Abstract][Full Text] [Related]
20. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
